The GPRC5D-directed therapies market is witnessing robust growth, driven by high unmet need in relapsed/refractory multiple ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Survivors are uniting to share their stories of being diagnosed in a bid to raise awareness of a condition that affects more ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...

A cancer thriver reflects on the emotional toll, survivorship, advocacy and support networks they wish they’d known at ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, shares how the company is ...

He was always giving back to the community and giving his best to the kids,” said former Central High School boys basketball ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...